Revance is positioned to launch RHA dermal fillers in the United States. RHA fillers are designed with a different crosslinking chemistry than traditional HA products, intended to maintain natural movement and flexibility in dynamic facial areas. The product line addresses a specific clinical niche: patients who want volume restoration without the "frozen" appearance associated with more rigid HA formulations.
Injectables
Revance Positioned to Launch RHA Fillers in U.S.
Revance is moving toward U.S. market entry with its RHA (Resilient Hyaluronic Acid) dermal filler line.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
RHA fillers target the dynamic-movement niche—but the market is already crowded.
For practices, this represents another entrant into an already crowded HA filler market. Revance's entry strategy will depend on pricing, rebate programs (Alle, Aspire, Evolus Rewards), and how aggressively they target injector education. The RHA positioning is clinically sound but not revolutionary—Galderma's Restylane Lyft and Allergan's Voluma already own significant market share in the dynamic-movement category. Revance will need strong MSO and distributor relationships to gain traction.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.